Mabion Capacity Update January 2025: Large Molecule Development

In our presentation, we will highlight Mabion’s expanded capabilities for large molecule development, with a strong focus on both upstream and downstream process development. We will also showcase our recently released capacity, including advanced bioreactors and our cutting-edge analytical portfolio. Join us on a tour of our GMP-certified facility, where we uphold the highest quality standards for clinical and commercial manufacturing.

Founded in 2007 and located in Central Europe, Mabion is a fully integrated CDMO specializing in the development and support of protein-based biotherapeutics, including monoclonal antibodies, vaccine antigens, and other large proteins. We offer a comprehensive end-to-end solution, covering every stage of biologic drug development—starting from early clone selection and small-scale manufacturing to process scale-up, large-scale production, and quality control. Our services also extend to sterile fill-finish, packaging and serialization, bioanalytics, and regulatory support, ensuring a seamless path from development to commercialization.